Haemonetics Appoints Martin Madaus to Board; Shareholders Approve Expanded Incentive Plan

Haemonetics announced the election of Dr. Martin Madaus to its Board of Directors, effective July 24, 2026. Concurrently, following its 2026 annual shareholder meeting, the company disclosed that shareholders approved an amendment to its long-term incentive plan, authorizing a significant number of additional shares for issuance.

Key Details

• Director Appointment: Dr. Martin Madaus, currently a Senior Operating Executive at The Carlyle Group, was elected to the Board. He is expected to be appointed to the Audit Committee and the Governance and Compliance Committee.
• Incentive Plan Expansion: Shareholders approved an amendment to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. This authorizes an additional 4,680,000 shares for issuance and extends the plan's term through 2036.
• ESPP Amendment: Shareholders also approved an amendment to the 2007 Employee Stock Purchase Plan (ESPP), primarily to extend its term through 2036.